EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%

被引：0

作者：

Rizvi, N. ^{[1
]}

Lee, S. ^{[2
]}

Curtis, P. ^{[2
]}

Caldwell, W. ^{[2
]}

Gao, B. ^{[2
]}

Rietschel, P. ^{[2
]}

机构：

[1] Columbia Univ, Med Ctr, New York, NY USA

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

Anti-PD-1; cemiplimab; REGN2810;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.04-26

引用

页码：S931 / S932

页数：2

共 50 条

[21] Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial Response
Makharadze, Tamta
Gogishvili, Miranda
Baramidze, Ana
Li, Siyu
Li, Yuntong
Pouliot, Jean-Francois
Seebach, Frank
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (07) : E74 - E75
[22] Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI plus CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Gogishvili, M.
Melkadze, T.
Baramidze, A.
Makharadze, T.
He, X.
Gullo, G.
Rietschel, P.
Quek, R. G. W.
ANNALS OF ONCOLOGY, 2023, 34
[23] A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%
Faulkner, Neil E.
Melkadze, Tamar
Nair, Santosh
Gabrail, Nashat
Kunta, Gopal
Ibrahim, Emad
Dreisbach, Luke
Brungs, Daniel
Chikhladze, Nana
Gogishvili, Miranda
Vokes, Natalie I.
Hiley, Tara
Nguyen, Christopher
Ghattas, Maria
Li, Siyu
Salvati, Mark
Lowy, Israel
Fury, Matthew G.
Paoluzzi, Luca
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Clingan, Philip R.
Sriuranpong, Virote
Rizvi, Naiyer A.
McGinniss, Jennifer
Pouliot, Jean-Francois
Lee, Sue
Seebach, Frank A.
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Gogishvili, M.
Melkadze, T.
Makharadze, T.
Giorgadze, D.
Dvorkin, M.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
Gessner, C.
Jaime, B. Moreno
Passalacqua, R.
Li, S.
McGuire, K.
Quek, R. G.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
[26] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Gogishvili, M.
Melkadze, T.
Makharadze, T.
Giorgadze, D.
Dvorkin, M.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
Gessner, C.
Moreno-Jaime, B.
Passalacqua, R.
Li, S.
McGuire, K.
Quek, R. G. W.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
[27] A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%
Awad, M. M.
Hao, Y.
Li, S.
Kaul, M.
Seebach, F.
Goncalves, P.
Brueck, P.
Rietschel, P.
ANNALS OF ONCOLOGY, 2023, 34
[28] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial
Ozguroglu, Mustafa
Kilickap, Saadettin
Sezer, Ahmet
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Nechaeva, Marina
Schenker, Michael
Cicin, Irfan
Ho, Gwo Fuang
Kulyaba, Yaroslav
Zyuhal, Kasimova
Scheusan, Roxana-Ioana
Garassino, Marina Chiara
He, Xuanyao
Kaul, Manika
Okoye, Emmanuel
Li, Yuntong
Li, Siyu
Pouliot, Jean-Francois
Seebach, Frank
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
LANCET ONCOLOGY, 2023, 24 (09): : 989 - 1001
[29] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
Baramidze, Ana
Makharadze, Tamta
Gogishvili, Miranda
Melkadze, Tamar
Giorgadze, Davit
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa
McIntyre, Debra A. G.
Perez, Javier
Kaul, Manika
Quek, Ruben G. W.
Seebach, Frank
Rietschel, Petra
Pouliot, Jean-Francois
LUNG CANCER, 2024, 193
[30] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more(EMPOWER-Lung 1):35-month follow-up from a multicentre,open-label,randomised,phase 3 trial
Mustafa ?zgüroglu
Saadettin Kilickap
Ahmet Sezer
Mahmut Gümüs
Igor Bondarenko
Miranda Gogishvili
Marina Nechaeva
Michael Schenker
Irfan Cicin
Gwo Fuang Ho
Yaroslav Kulyaba
Kasimova Zyuhal
Roxana-loana Scheusan
Marina Chiara Garassino
Xuanyao He
Manika Kaul
Emmanuel Okoye
Yuntong Li
Siyu Li
Jean-Francois Pouliot
Frank Seebach
Israel Lowy
Giuseppe Gullo
Petra Rietschel
房超
肿瘤药学, 2023, 13 (04) : 384 - 384

← 1 2 3 4 5 →

EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 &lt;50%

EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%